Diferencia entre revisiones de «Ketorolac»
(Switch SMW query from broadtable to table format for better layout with TOC) |
|||
| (No se muestran 23 ediciones intermedias de 7 usuarios) | |||
| Línea 1: | Línea 1: | ||
==General== | ==General== | ||
*Type: [[NSAID]] | *Type: [[NSAID]] | ||
*Dosage Forms: | *Dosage Forms: 15mg/mL, 30mg/mL injection | ||
*Common Trade Names: Toradol | *Common Trade Names: Toradol | ||
''Although standard packaging provides 30mg doses current research demonstrates that the analgesic ceiling for ketorolac appears to be 10 mg if given intravenously''<ref> Motov S et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med 2016. PMID: 27993418</ref> | |||
==Adult Dosing== | ==Adult Dosing== | ||
*Acute pain: | |||
**IM: 15mg x 1 or 15mg q6h | |||
**IV: 15mg x 1, then 15mg q6h | |||
**Black box warning against treatment for > 5 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*N/A | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: | *Lactation: Enters breast milk, use caution | ||
*Elderly (> 65 yo): Decrease dose by 50% | |||
*Renal Dosing | *Renal Dosing | ||
** | **Mild-Moderate impairment: Decrease dose by 50% | ||
** | **Severe impairment or HD: Contraindicated | ||
*Hepatic Dosing | *Hepatic Dosing: No dose change, but may increase LFTs | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Active or prior [[PUD]], recent [[GI bleed]] | |||
*Severe renal disease or HD | |||
*Bleeding diathesis | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Bleeding, MI, CVA, GI bleed/perforation, Hyperkalemia | |||
===Common=== | ===Common=== | ||
*Dyspepsia, nausea, headache | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Onset: 20-30 minutes | ||
*Metabolism: | *Peak: 2-3 hours | ||
*Excretion: | *Duration: 4-6 hours | ||
*Mechanism of Action: | *Half-life: 2-6 hours, up to 19 hours in renal disease | ||
*Metabolism: Hepatic | |||
*Excretion: Renal | |||
*Mechanism of Action: NSAID, Reversible COX-1/2 inhibitor | |||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Ketorolac]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
*[[NSAID toxicity]] | |||
== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
Revisión actual - 21:56 20 mar 2026
General
- Type: NSAID
- Dosage Forms: 15mg/mL, 30mg/mL injection
- Common Trade Names: Toradol
Although standard packaging provides 30mg doses current research demonstrates that the analgesic ceiling for ketorolac appears to be 10 mg if given intravenously[1]
Adult Dosing
- Acute pain:
- IM: 15mg x 1 or 15mg q6h
- IV: 15mg x 1, then 15mg q6h
- Black box warning against treatment for > 5 days
Pediatric Dosing
- N/A
Special Populations
- Pregnancy Rating: C
- Lactation: Enters breast milk, use caution
- Elderly (> 65 yo): Decrease dose by 50%
- Renal Dosing
- Mild-Moderate impairment: Decrease dose by 50%
- Severe impairment or HD: Contraindicated
- Hepatic Dosing: No dose change, but may increase LFTs
Contraindications
- Allergy to class/drug
- Active or prior PUD, recent GI bleed
- Severe renal disease or HD
- Bleeding diathesis
Adverse Reactions
Serious
- Bleeding, MI, CVA, GI bleed/perforation, Hyperkalemia
Common
- Dyspepsia, nausea, headache
Pharmacology
- Onset: 20-30 minutes
- Peak: 2-3 hours
- Duration: 4-6 hours
- Half-life: 2-6 hours, up to 19 hours in renal disease
- Metabolism: Hepatic
- Excretion: Renal
- Mechanism of Action: NSAID, Reversible COX-1/2 inhibitor
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Acute pain management | 15-30 mg IV q6h or 30-60 mg IM | Non-opioid analgesic (NSAID, parenteral) | IV/IM | Adult |
| Corneal abrasion | 1 drop 0.4% q6hr x 2-3 days | Ophthalmic NSAID for pain | Topical ophthalmic | Adult |
| Headache | 15-30 mg IV (30-60 mg IM) | NSAID for headache | IV/IM | Adult |
| Migraine headache | 15-30 mg IV | NSAID adjunct | IV | Adult |
| Migraine headache | 15-30 mg IV (30-60 mg IM) | NSAID for headache | IV/IM | Adult |
| Sickle cell crisis | 15 mg q6hr | NSAID for vaso-occlusive crisis | IV | Adult |
| Urolithiasis | 15mg | First-line analgesic | IV | Adult |
See Also
References
- ↑ Motov S et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med 2016. PMID: 27993418